FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Clinical Trials Arena on MSN
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient deathIntellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...
Intellia Therapeutics Inc. shares dropped after the company said a patient died after suffering liver damage in a clinical trial for the company’s gene-editing treatment. The patient, who was in his ...
Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who experienced a liver-related adverse event in a Phase 3 trial for its nex-z ...
WASHINGTON (AP) — The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that’s been linked to two patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback